Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.18 is 65% below its 5-year average of -0.72, near the low end of its 5-year range (-1.18–-0.43).
47.50% below its 12-month average of -0.80.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.38.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.18
EARNINGS PER SHARE (EPS) AVG TTM
-0.80
EARNINGS PER SHARE (EPS) AVG 3Y
-0.80
EARNINGS PER SHARE (EPS) AVG 5Y
-0.72
EARNINGS PER SHARE (EPS) AVG 10Y
-1.24
EARNINGS PER SHARE (EPS) AVG 15Y
-1.95
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-47.50%
CURRENT VS 3Y AVG
-48.43%
CURRENT VS 5Y AVG
-64.65%
CURRENT VS 10Y AVG
+5.19%
CURRENT VS 15Y AVG
+39.60%
CURRENT VS 20Y AVG
N/A
ClearPoint Neuro, Inc.
Market Cap
$345.48M
Earnings Per Share (EPS)
-1.18
TTM Avg
-0.80
3Y Avg
-0.80
5Y Avg
-0.72
Market Cap
$348.59M
Earnings Per Share (EPS)
-3.31
TTM Avg
-3.43
3Y Avg
-2.65
5Y Avg
-2.61
Market Cap
$348.85M
Earnings Per Share (EPS)
1.48
TTM Avg
1.49
3Y Avg
2.03
5Y Avg
3.82
Market Cap
$339.15M
Earnings Per Share (EPS)
-1.58
TTM Avg
-1.99
3Y Avg
-1.86
5Y Avg
-1.78
Market Cap
$330.60M
Earnings Per Share (EPS)
-1.00
TTM Avg
-1.40
3Y Avg
-2.02
5Y Avg
-1.91
Market Cap
$329.01M
Earnings Per Share (EPS)
-0.63
TTM Avg
-0.48
3Y Avg
-0.42
5Y Avg
-0.42
Market Cap
$363.54M
Earnings Per Share (EPS)
2.65
TTM Avg
-5.30
3Y Avg
-10.00
5Y Avg
-10.52
Market Cap
$366.39M
Earnings Per Share (EPS)
-2.41
TTM Avg
-4.66
3Y Avg
-5.40
5Y Avg
-4.56
Market Cap
$368.91M
Earnings Per Share (EPS)
-0.14
TTM Avg
-0.19
3Y Avg
-0.48
5Y Avg
-0.56
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ClearPoint Neuro, Inc. (CLPT) | $345.48M | -1.18 | -0.80 | -0.80 | -0.72 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | -3.31 | -3.43 | -2.65 | -2.61 |
| Embecta Corp. (EMBC)vs › | $348.85M | 1.48 | 1.49 | 2.03 | 3.82 |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | -1.58 | -1.99 | -1.86 | -1.78 |
| C4 Therapeutics, Inc. (CCCC)vs › | $330.60M | -1.00 | -1.40 | -2.02 | -1.91 |
| CapsoVision, Inc. (CV)vs › | $329.01M | -0.63 | -0.48 | -0.42 | -0.42 |
| Agenus Inc. (AGEN)vs › | $363.54M | 2.65 | -5.30 | -10.00 | -10.52 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -2.41 | -4.66 | -5.40 | -4.56 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $368.91M | -0.14 | -0.19 | -0.48 | -0.56 |
| Canopy Growth Corporation (CGC)vs › | $373.40M | -0.50 | -5.17 | -17.19 | -12.52 |
Trailing EPS (TTM)
$-1.18
Forward EPS (Est.)
$-1.30
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.90 |
| 2024-12-31 | -0.70 |
| 2023-12-31 | -0.90 |
| 2022-12-31 | -0.68 |
| 2021-12-31 | -0.69 |
| 2020-12-31 | -0.43 |
| 2019-12-31 | -0.49 |
| 2018-12-31 | -0.56 |
| 2017-12-31 | -0.93 |
| 2016-12-31 | -2.93 |
| 2015-12-31 | -4.48 |
| 2014-12-31 | -3.06 |
| 2013-12-31 | -4.95 |
| 2012-12-31 | -5.65 |
| 2011-12-31 | -20.73 |
| 2010-12-31 | -23.76 |
